Literature DB >> 14583061

Health risks of counterfeit pharmaceuticals.

Martijn ten Ham1.   

Abstract

Pharmaceutical products are not exempt from the practice of counterfeiting. In recent years, many reports have become available demonstrating the presence of fake medicines on the market. Several studies have demonstrated that they are quite often of bad quality. It is estimated that 5% of all world trade in branded goods is counterfeit, leading to huge financial losses for the pharmaceutical industry. But much more important, from a public health point of view, is that history has shown that such products may lead to a great health risk. The essence of counterfeit products and the reason they are so dangerous is the complete absence of quality control, since they are often indistinguishable from the genuine product. The existence of counterfeit drugs has long been ignored both by the pharmaceutical industry and by drug regulatory authorities. At present initiatives are being taken, nationally and internationally, to curb counterfeiting. It is now realised that a strong regulatory agency is essential, but the initiatives can only be successful if all parties concerned actively co-operate.

Mesh:

Substances:

Year:  2003        PMID: 14583061     DOI: 10.2165/00002018-200326140-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  1 in total

1.  Counterfeit drugs: implications for health.

Authors:  M ten Ham
Journal:  Adverse Drug React Toxicol Rev       Date:  1992
  1 in total
  7 in total

1.  What is drug safety?: celebrating 20 years of the Drug Safety journal.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Substandard/counterfeit antimicrobial drugs.

Authors:  Theodoros Kelesidis; Matthew E Falagas
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  Quality of chloroquine tablets available in Africa.

Authors:  C W Sawadogo; M Amood Al-Kamarany; H M Al-Mekhlafi; M Elkarbane; A H Al-Adhroey; Y Cherrah; A Bouklouze
Journal:  Ann Trop Med Parasitol       Date:  2011-09

4.  Quality of medicines commonly used in the treatment of soil transmitted helminths and giardia in ethiopia: a nationwide survey.

Authors:  Sultan Suleman; Gemechu Zeleke; Habtewold Deti; Zeleke Mekonnen; Luc Duchateau; Bruno Levecke; Jozef Vercruysse; Matthias D'Hondt; Evelien Wynendaele; Bart De Spiegeleer
Journal:  PLoS Negl Trop Dis       Date:  2014-12-04

5.  Drug shortages in Saudi Arabia: Root causes and recommendations.

Authors:  Yazed S Alruthia; Monira Alwhaibi; Mashal F Alotaibi; Shatha A Asiri; Bushra M Alghamdi; Ghadah S Almuaythir; Wejdan R Alsharif; Hala H Alrasheed; Yahya A Alswayeh; Abdulaziz J Alotaibi; Mohammad Almeshal; Saleh N Aldekhail; Abdulrahman Alhusaini; Sulaiman A Alrashed; Ali M Alrumaih; Mohammed A Dahhas; Mohammed A Alghamdi; Mohammad S Aleheidib; Mohamed H Alhaidari; Jameel A Alharbi; Aws Alshamsan
Journal:  Saudi Pharm J       Date:  2018-05-12       Impact factor: 4.330

6.  Advancing pharmaceuticals and patient safety in Saudi Arabia: A 2030 vision initiative.

Authors:  Tariq M Alhawassi; Hatem A Abuelizz; Mansour Almetwazi; Mansour A Mahmoud; Ahmed Alghamdi; Yazed S Alruthia; Nasser BinDhim; Khalid A Alburikan; Yousif A Asiri; Peter J Pitts
Journal:  Saudi Pharm J       Date:  2017-10-21       Impact factor: 4.330

7.  Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.

Authors:  Sachiko Ozawa; Daniel R Evans; Sophia Bessias; Deson G Haynie; Tatenda T Yemeke; Sarah K Laing; James E Herrington
Journal:  JAMA Netw Open       Date:  2018-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.